Partner Content - Pharmaphorum

Latest Partner content

in Partner content Partner Content

Introducing SMi’s 5th conference on Drug Safety 2018 this June 2018
March 7, 2018 Share
X
Introducing SMi’s 5th conference on Drug Safety 2018 this June 2018
https://pharmaphorum.com/partner-content-market-access/introducing-smis-5th-conference-on-drug-safety-2018-this-june-2018/
in Partner content Partner Content

Six pharma firms to participate at Pharmaceutical Microbiology event in San Diego
March 1, 2018 Share
X
Six pharma firms to participate at Pharmaceutical Microbiology event in San Diego
https://pharmaphorum.com/partner-content-market-access/six-pharma-firms-to-participate-at-pharmaceutical-microbiology-event-in-san-diego/

Latest developments and breakthroughs in antibiotic resistance

The growing global threat of antimicrobial resistance, research strategies aiming to eliminate resistance, latest scientific advancements for tackling

Latest developments and breakthroughs in antibiotic resistance

https://pharmaphorum.com/partner-content-market-access/latest-developments-breakthroughs-antibiotic-resistance/

Intellectual Property and Regulatory Law: Recent Developments

Parallel Trade 2018

Intellectual Property and Regulatory Law: Recent Developments

https://pharmaphorum.com/partner-content-market-access/intellectual-property-and-regulatory-law-recent-developments/

Attendee list for Biosimilars North America 2017 released

Attendee list for Biosimilars North America 2017 releas

Attendee list for Biosimilars North America 2017 released

https://pharmaphorum.com/partner-content-market-access/attendee-list-for-biosimilars-north-america-2017-released/

Intellectual Property and Regulatory Law: Recent Developments | Parallel Trade 2018

Intellectual Property Law

Intellectual Property and Regulatory Law: Recent Developments | Parallel Trade 2018

https://pharmaphorum.com/partner-content-market-access/intellectual-property-and-regulatory-law-recent-developments-parallel-trade-2018/

Can parallel distribution and industry work together?

https://pharmaphorum.com/partner-content-market-access/can-parallel-distribution-and-industry-work-together/

Industry experts set to transform evolving pre-approval & unlicensed medicines sector with launch of Inceptua Medicines Access

Created in response to unprecedented global demand from patients and physicians and to provide a long-sought after alternative

Industry experts set to transform evolving pre-approval & unlicensed medicines sector with launch of Inceptua Medicines Access

https://pharmaphorum.com/partner-content-market-access/industry-experts-set-transform-evolving-pre-approval-unlicensed-medicines-sector-launch-inceptua-medicines-access/

Orphan medicines, advances, access and affordability

LONDON, UNITED KINGDOM, April 19th 2017: The number of orphan drug candidates gaining European market authorisation has risen

Orphan medicines, advances, access and affordability

https://pharmaphorum.com/partner-content-market-access/orphan-medicines-advances-access-affordability/

Does NEMO bring us a step closer in the fight against melanoma?

Options for treatment in metastatic melanoma have increased significantly in terms of efficacy and reduction of mortality in

Does NEMO bring us a step closer in the fight against melanoma?

https://pharmaphorum.com/partner-content-oncology/nemo-bring-us-step-closer-fight-melanoma/

The HNSCC immunotherapy race is on – and it’s going to be close

While improper to compare life saving treatments to buses – the metaphor when it comes to head and

The HNSCC immunotherapy race is on – and it’s going to be close

https://pharmaphorum.com/partner-content-oncology/hnscc-immunotherapy-race-going-close/

Further Darzalex results extend hope for PFS in Myeloma

Earlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its

Further Darzalex results extend hope for PFS in Myeloma

https://pharmaphorum.com/partner-content-oncology/further-darzalex-results-extend-hope-for-pfs-in-myeloma/

Positive PIII results for VYXEOS revealed at ASCO

Building on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the

Positive PIII results for VYXEOS revealed at ASCO

https://pharmaphorum.com/partner-content-oncology/positive-piii-results-for-vyxeos-revealed-at-asco/

What are the key presentations at ASCO 2016?

The 2016 American Society of Clinical Oncology (ASCO) annual meeting starts today (3rd June), and it promises to

What are the key presentations at ASCO 2016?

https://pharmaphorum.com/partner-content-oncology/what-are-the-key-presentations-at-asco-2016/

See all

Trending

Latest Partner content

Introducing SMi’s 5th conference on Drug Safety 2018 this June 2018

Six pharma firms to participate at Pharmaceutical Microbiology event in San Diego

More Partner Content

Latest developments and breakthroughs in antibiotic resistance

Intellectual Property and Regulatory Law: Recent Developments

Attendee list for Biosimilars North America 2017 released

Intellectual Property and Regulatory Law: Recent Developments | Parallel Trade 2018

Can parallel distribution and industry work together?

Industry experts set to transform evolving pre-approval & unlicensed medicines sector with launch of Inceptua Medicines Access

Orphan medicines, advances, access and affordability

Does NEMO bring us a step closer in the fight against melanoma?

The HNSCC immunotherapy race is on – and it’s going to be close

Further Darzalex results extend hope for PFS in Myeloma

Positive PIII results for VYXEOS revealed at ASCO

What are the key presentations at ASCO 2016?

Search

Advanced Search

Trending

Latest Partner content

More Partner Content